logo
logo

Qihan Biotech Raises Additional Usd 67 Million In Series A++ Financing

Mar 29, 2021•over 4 years ago

Amount Raised

$67 Million

Round Type

series a

Hangzhou

Description

Qihan Biotechnology Co. Ltd ( or ), a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ financing. Proceeds from the financing will primarily be used to advance Qihan’s pipeline of novel cell therapies in IND-enabling studies and hypoimmunity projects, and expansion of the company’s GMP manufacturing facilities.

Company Information

Company

Qihan Biotech

Location

Hangzhou, Zhejiang, China

About

Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation. The company’s mission is to use high-throughput, multiplexable genome editing in combination with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other important medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised a total of $100 million in fundraising and is advancing its cell therapy programs into IND-enabling investigations. Qihan Biotech is headquartered in Hangzhou, China. For more information, please visit www.qihanbio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech